Michael Siluk | UCG | Common Photos Group | Getty Photos
Novo Nordisk rose as a lot as 4% after England’s drug value watchdog really helpful the usage of its best-selling drug Wegovy to stop coronary heart assaults and strokes, marking the primary GLP-1 backed for this use within the nation.
Wegovy is especially a weight reduction remedy however it is usually accepted for lowering the chance of main cardiovascular occasions in folks dwelling with obese or weight problems.
The brand new advice the Nationwide Institute for Well being and Care Excellence (NICE), England’s drug value regulator, will considerably develop entry to Wegovy on the nation’s Nationwide Well being Service (NHS).
Round 1.2 million folks might use the drugs to assist shield them in opposition to having additional coronary heart assaults or strokes, as it’s made accessible for this situation, NICE stated in a press release on Wednesday.
The regulator, which assesses a drugs’s cost-effectiveness, really helpful semaglutide, the energetic ingredient in Wegovy and diabetes remedy Ozempic, as an possibility for adults who’ve beforehand had a coronary heart assault, a stroke, or a severe circulation downside within the legs and who’ve a physique mass index (BMI) of a minimum of 27.
Novo’s Copenhagen-listed shares had been final seen up 1.7% in morning buying and selling, paring some earlier positive factors. The pan-European blue-chip index Stoxx 600 was up 1.8%.
Scientific trials have proven that sufferers taking a 2.4 mg dose of semaglutide alongside current cardiovascular medicines had been 20% much less more likely to have a severe cardiovascular occasion in comparison with placebo.
Wegovy secured UK approval in 2024 for lowering the chance of main heart problems in folks dwelling with obese or weight problems and coronary heart illness, however entry to the drugs was restricted to sufferers paying out-of-pocket if used to deal with these situations.
Novo Nordisk has confronted a number of setbacks over the previous 12 months because it has misplaced market share to U.S.-based rival Eli Lilly, whose medicines have resulted in additional pronounced weight reduction at accepted doses. It is usually dealing with vital pricing stress amid political stress in its largest market, the U.S., to decrease the prices of pharmaceuticals, in addition to publicity to generic competitors in India and different markets this 12 months.
Thus far in 2026, Novo has launched Wegovy in a tablet as the primary oral GLP-1 for weight reduction, and higher-dose Wegovy that’s extra on par with Lilly’s rival Zepbound, because it’s making an attempt to claw again market share.
Coronary heart and circulatory illness is likely one of the main causes of early loss of life and sick well being in England, and about 1 in 4 adults within the U.Ok. is estimated to dwell with weight problems, in accordance with the NHS.
Wegovy shall be included for treating heart problems and alongside NICE’s current steering recommending semaglutide for weight administration in adults dwelling with weight problems or obese.
“Collectively, these selections mirror the rising physique of proof that this class of medicines provides advantages extending past weight reduction,” NICE stated.
“As we speak’s NICE advice for Wegovy is a vital step ahead for folks dwelling with established heart problems and obese or weight problems,” stated Sebnem Avsar Tuna, basic supervisor at Novo Nordisk U.Ok.
“It means clinicians in England now have entry to an extra remedy that NICE has discovered to be value efficient, the primary and solely GLP 1 receptor agonist confirmed to cut back the chance of coronary heart assault, stroke or cardiovascular loss of life on this excessive danger inhabitants.”